Damon Reed

Dr. Damon Reed

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
HTHussein A Tawbi
Hussein A Tawbi
MBMelissa Burgess
Melissa Burgess
VBVanessa Bolejack
Vanessa Bolejack
BTBrian A Van Tine
Brian A Van Tine
SSScott M Schuetze
Scott M Schuetze
SPShreyaskumar Patel
Shreyaskumar Patel

1 August 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
WTWilliam D. Tap
William D. Tap
ZPZsuzsanna Papai
Zsuzsanna Papai
BTBrian A Van Tine
Brian A Van Tine
SASteven Attia
Steven Attia
KGKristen N Ganjoo
Kristen N Ganjoo
PSPatrick Schöffski
Patrick Schöffski

10 February 2017 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
JBJ. Sybil Biermann
J. Sybil Biermann
WCWarren Chow
Warren Chow
DRDamon Reed
Damon Reed
DLDavid Lucas
David Lucas
DADouglas R. Adkins
Douglas R. Adkins
JSJillian L. Scavone
Jillian L. Scavone
The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed. The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed.

2 January 2018 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
PCPeter F. Coccia
Peter F. Coccia
APAlberto S. Pappo
Alberto S. Pappo
LBLynda Beaupin
Lynda Beaupin
VBVirginia F. Borges
Virginia F. Borges
SBScott C. Borinstein
Scott C. Borinstein
DSDorothy A. Shead
Dorothy A. Shead
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on treatment and management considerations for AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for AYA Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.

1 February 2015 in Patient Related Outcome Measures
Verified
Journal Article
Open access
PDF file
GQGwendolyn Quinn
Gwendolyn Quinn
VGVânia Gonçalves
Vânia Gonçalves
ISIvana Sehovic
Ivana Sehovic
MBMeghan L Bowman
Meghan L Bowman
DRDamon Reed
Damon Reed
Introduction: Adolescent and young adult (AYA) cancer survivors experience many unique challenges and quality of life (QoL) effects that persist beyond cancer diagnosis and treatment. Due to continuous improvements in technology and cancer treatments resulting in improved survival rates, the identification of late effects, survivorship issues, and QoL is moving to the forefront of cancer research. The goal of this systematic review was to identify key psychosocial factors impacting QoL in AYA oncology populations. Methods: A systematic review of the literature was conducted using combinations of these phrases or keywords: “adolescent and young adult or AYA” AND “health outcomes OR quality of life OR psychology” AND “neoplasm OR cancer OR oncology”. A total of 35 articles were included in this review. Studies were classified into two categories: AYA perceptions and stakeholder perceptions. Results: AYA cancer survivors were more likely to have “worse” or impaired QoL compared with the general population, regardless of other demographic factors. AYAs described both positive and negatives experiences with their medical care, the educational information received, and the supportive care services. Although health care professionals were likely to underestimate or misjudge the health preferences and support needs of AYAs, these perceptions varied across disciplines and levels of experience. Conclusion: The literature is lacking in sufficient evidence-based interventions to improve QoL in AYA cancer populations. Further, the tools to adequately measure QoL in this population are also unsatisfactory. The literature, however, consistently shows agreement regarding the unique needs of this population, indicating a trend toward health care standardization within age ranges or life stages. We suggest the need for AYA-specific programs in health care institutions that comprise a multidisciplinary team that addresses all the unique medical and QoL needs of AYAs.

28 April 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
AFAnna Maria Frezza
Anna Maria Frezza
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
EBElizabeth H. Baldini
Elizabeth H. Baldini
SBSylvie Bonvalot
Sylvie Bonvalot
ATAnnalisa Trama
Annalisa Trama